ADIL Stock Price, Adial Pharmaceuticals Quote, Chart

Market Summary

USD1.61-0.09

Market Closed

-5.29%

ADIL Stock Price

View Fullscreen

ADIL RSI Chart

ADIL Valuation

Market Cap

6.9M

Price/Earnings (Trailing)

-1.35

EV/EBITDA

-0.55

Price/Free Cashflow

-1.01

MarketCap/EBT

-0.94

ADIL Price/Sales (Trailing)

ADIL Profitability

Return on Equity

-125.46%

Return on Assets

-108.16%

Free Cashflow Yield

-98.75%

ADIL Fundamentals

ADIL Earnings

Earnings (TTM)

-5.1M

Earnings Growth (Yr)

33.01%

Earnings Growth (Qtr)

-38.65%

Breaking Down ADIL Revenue

Last 7 days

5.6%

Last 30 days

37.1%

Last 90 days

51.8%

Trailing 12 Months

466.7%

How does ADIL drawdown profile look like?

ADIL Financial Health

Current Ratio

4.9

ADIL Investor Care

Shares Dilution (1Y)

255.48%

Diluted EPS (TTM)

-3.66

Tracking the Latest Insider Buys and Sells of Adial Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 29, 2023	schuyler kevin	bought	1,918	2.74	700	-
May 23, 2023	truluck joseph	acquired	-	-	157,500	chief financial officer
May 23, 2023	stilley william b. iii	acquired	-	-	240,800	-
May 23, 2023	claiborne cary j	acquired	-	-	420,000	chief executive officer
Dec 30, 2022	stilley william b. iii	back to issuer	-	-	-166,667	-
Sep 20, 2022	claiborne cary j	acquired	31,515	0.4202	75,000	chief executive officer
Sep 19, 2022	claiborne cary j	acquired	10,735	0.4294	25,000	chief executive officer
Aug 18, 2022	claiborne cary j	acquired	-	-	1,000,000	chief executive officer
Feb 23, 2022	stilley william b. iii	acquired	-	-	250,000	chief executive officer
Dec 30, 2021	newman james w. jr.	bought	13,600	2.72	5,000	-

Which funds bought or sold ADIL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 29, 2024	BENJAMIN F. EDWARDS & COMPANY, INC.	unchanged	-	-	-	-%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	new	-	27,508	27,508	-%
Feb 14, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	new	-	7,875	7,875	-%
Feb 13, 2024	MORGAN STANLEY	reduced	-57.14	-41.00	17.00	-%
Feb 13, 2024	Qube Research & Technologies Ltd	unchanged	-	-6.00	15.00	-%
Feb 13, 2024	ARMISTICE CAPITAL, LLC	new	-	295,740	295,740	-%
Feb 13, 2024	BlackRock Inc.	unchanged	-	-7,027	14,209	-%
Feb 13, 2024	RENAISSANCE TECHNOLOGIES LLC	new	-	43,000	43,000	-%

Are Funds Buying or Selling ADIL?

Are funds buying ADIL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ADIL

No. of Funds

Unveiling Adial Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.99%	166,972	SC 13G
Feb 14, 2022	peikin mark howard	4.4%	904,444	SC 13G/A
Aug 18, 2021	peikin mark howard	6.67%	1,346,741	SC 13G/A
Aug 13, 2021	peikin mark howard	5.52%	1,120,241	SC 13G
Aug 13, 2021	stilley william b. iii	9.38%	2,005,752	SC 13D/A
Feb 16, 2021	armistice capital, llc	4.5%	712,500	SC 13G/A
Feb 08, 2021	stilley william b. iii	11.1%	1,769,363	SC 13D/A
Dec 11, 2020	stilley william b. iii	9.97%	1,513,310	SC 13D/A
Jun 19, 2020	armistice capital, llc	5.0%	712,500	SC 13G
Jun 18, 2020	intracoastal capital, llc	3.4%	470,000	SC 13G

Recent SEC filings of Adial Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	8-K	Current Report
Apr 23, 2024	424B3	Prospectus Filed
Apr 19, 2024	EFFECT	EFFECT
Apr 18, 2024	424B5	Prospectus Filed
Apr 18, 2024	8-K	Current Report
Apr 16, 2024	8-K	Current Report
Apr 12, 2024	S-3	S-3
Apr 01, 2024	10-K	Annual Report
Mar 27, 2024	4	Insider Trading
Mar 27, 2024	4	Insider Trading

Peers (Alternatives to Adial Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.8B	6.8B	23.52%	-6.94%	-7.84	6.83	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.1B	2.0B	0.99%	-25.83%	-57.6	9.55	75.20%	68.82%
BMRN	15.6B	2.5B	-4.94%	-13.58%	75.88	6.31	13.74%	186.89%
INCY	12.1B	3.8B	-2.80%	-18.78%	16.29	3.22	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-16.72%	-43.78%	-10.83	14.43	425.83%	18.94%
BBIO	5.3B	107.9M	-4.79%	106.15%	-9.62	48.09	54.84%	-28.31%
AXSM	3.6B	270.6M	1.74%	5.10%	-15.04	13.29	440.80%	-27.84%
ARWR	3.1B	240.7M	-7.74%	-39.00%	-10.5	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.55%	-20.97%	-45.71	3.86	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.91%	-11.58%	24.74	4.44	85.90%	-14.05%
NVAX	666.2M	983.7M	8.15%	-35.14%	-1.22	0.68	-50.36%	17.16%
CRBP	407.3M	881.7K	0.99%	345.87%	-9.13	466.16	-77.61%	-5.33%
INO	277.6M	4.9M	-1.94%	21.49%	-2.05	57.05	-54.97%	51.71%
IBIO	6.9M	2.1M	-32.65%	86.79%	-0.25	2.14	-13.45%	66.37%

Adial Pharmaceuticals Inc News

Latest updates

Adial Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	65.2%	4,737	2,867	3,779	3,902	5,733	7,742	10,923	13,964	7,475	10,446	8,063	8,625	5,491	8,178	9,475	5,941	7,680	9,507	10,687	12,060	4,699
Current Assets	181.7%	3,199	1,135	2,047	2,965	4,780	6,773	9,940	12,965	6,462	7,986	5,590	6,172	5,136	8,172	9,469	5,935	7,673	9,501	10,681	12,053	4,693
Cash Equivalents	795.0%	2,827	316	1,218	2,313	4,002	5,753	9,157	12,689	6,062	7,180	5,210	5,638	4,401	7,365	8,624	4,952	6,777	8,530	10,254	11,394	3,869
Net PPE	-	-	-	-	48.00	50.00	52.00	54.00	56.00	58.00	62.00	62.00	30.00	-	-	-	-	-	-	-	-	-
Goodwill	-	-	-	-	249	249	249	249	249	249	131	131	131	-	-	-	-	-	-	-	-	-
Liabilities	23.6%	653	528	462	2,462	2,456	2,333	2,962	3,256	3,967	3,246	3,234	3,008	1,505	-	-	-	-	-	-	-	-
Current Liabilities	23.6%	653	528	462	1,798	1,791	1,327	1,867	2,171	2,722	1,958	2,213	2,042	1,505	1,093	682	390	539	777	627	329	258
Shareholder's Equity	74.6%	4,084	2,339	3,317	1,440	3,276	5,409	7,961	10,707	3,508	7,200	4,829	5,618	3,986	7,085	8,793	5,551	7,141	8,730	10,061	11,731	4,441
Retained Earnings	-2.9%	-68,797	-66,877	-65,492	-66,580	-63,674	-60,807	-57,698	-53,850	-50,943	-45,112	-40,800	-36,353	-31,519	-28,050	-24,714	-22,903	-20,626	-18,568	-16,852	-14,718	-12,035
Additional Paid-In Capital	5.3%	72,880	69,216	68,809	67,992	66,950	66,190	65,634	64,535	54,430	52,292	45,605	41,954	35,491	35,121	33,494	28,444	27,757	27,288	26,903	26,439	16,470
Shares Outstanding	36.6%	1,663	1,218	1,198	1,141	1,067	1,074	1,034	926	838	715	674	691	576	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	31,265	-	-	-	40,504	-	-	-	14,669	-	-	-	12,307	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	12.1%	-1,222	-1,390	-1,894	-2,298	-1,750	-3,403	-3,534	-2,496	-2,373	-3,529	-3,203	-2,843	-2,614	-2,208	-985	-1,825	-1,752	-1,724	-1,140	-1,721	-1,103
Share Based Compensation	4.6%	281	268	738	460	734	557	1,100	984	884	1,189	843	1,325	370	678	395	571	469	385	464	284	300
Cashflow From Investing	0%	350	350	-	-	-	-	-	-	-	-	-33.73	-286*	-	-	-	-	-	-	-	-	-
Cashflow From Financing	2340.2%	3,384	139	58*	610	-	-	2.00	9,124	1,255	5,500	2,809	4,081	-	950	-	-	109*	178*	26*	9,246	156

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ADIL Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Operating Expenses:
Research and development	$ 1,267,077	$ 1,950,308
General and administrative	5,620,870	8,909,167
Total Operating Expenses	6,887,947	10,859,475
Loss From Operations	(6,887,947)	(10,859,475)
Other Income (Expense)
Interest income	69,779	63,338
Loss on equity method investment	(193,884)
Other income	10,162
Total other income (expense)	(113,943)	63,338
Loss Before Provision For Income Taxes	(7,001,890)	(10,796,137)
Income tax benefit
Loss from Continuing Operations	(7,001,890)	(10,796,137)
Income (loss) from discontinued operations, net of taxes, including gain on disposal of $2,624,798	1,878,549	(1,935,279)
Net Loss	$ (5,123,341)	$ (12,731,416)
Loss per share from continuing operations, basic and diluted (in Dollars per share)	$ (4.91)	$ (10.78)
Income (loss) per share from discontinued operations, basic (in Dollars per share)	1.32	(1.93)
Net loss per share, basic (in Dollars per share)	$ (3.6)	$ (12.71)
Weighted average shares, basic (in Shares)	1,424,661	1,001,505

ADIL Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 2,827,082	$ 4,001,794
Prepaid expenses and other current assets	371,597	349,441
Current assets of discontinued operations		428,700
Total Current Assets	3,198,679	4,779,935
Intangible assets, net	3,913	4,477
Equity method investment	1,534,013
Assets of discontinued operations		948,392
Total Assets	4,736,605	5,732,804
Current Liabilities:
Accounts payable	103,325	276,410
Accounts payable, related party	24,062
Accrued expenses	477,747	963,327
Accrued expenses, related party	47,942	175,000
Other current liabilities		10,387
Current liabilities of discontinued operations		365,742
Total Current Liabilities	653,076	1,790,866
Long-term Liabilities:
Long-term liabilities of discontinued operations		665,444
Total Liabilities	653,076	2,456,310
Commitments and contingencies – see Note 9
Stockholders’ Equity
Preferred Stock, 5,000,000 shares authorized with a par value of $0.001 per share, 0 shares outstanding at December 31, 2023 and 2022
Common Stock, 50,000,000 shares authorized with a par value of $0.001 per share, 1,663,421 and 1,067,491 shares issued and outstanding at December 31, 2023 and 2022, respectively	1,663	1,067
Additional paid in capital	72,879,738	66,949,958
Accumulated deficit	(68,797,872)	(63,674,531)
Total Stockholders’ Equity	4,083,529	3,276,494
Total Liabilities and Stockholders’ Equity	$ 4,736,605	$ 5,732,804

About Adial Pharmaceuticals Inc

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

CEO	Mr. Cary John Claiborne MBA
WEBSITE	adialpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	16

Adial Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Adial Pharmaceuticals Inc? What does ADIL stand for in stocks?

ADIL is the stock ticker symbol of Adial Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Adial Pharmaceuticals Inc (ADIL)?

As of Fri May 03 2024, market cap of Adial Pharmaceuticals Inc is 6.89 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ADIL stock?

You can check ADIL's fair value in chart for subscribers.

What is the fair value of ADIL stock?

You can check ADIL's fair value in chart for subscribers. The fair value of Adial Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Adial Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ADIL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Adial Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ADIL is over valued or under valued. Whether Adial Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Adial Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADIL.